BULLOUS PEMPHIGOID
Clinical trials for BULLOUS PEMPHIGOID explained in plain language.
Never miss a new study
Get alerted when new BULLOUS PEMPHIGOID trials appear
Sign up with your email to follow new studies for BULLOUS PEMPHIGOID, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could an asthma drug tame this brutal blistering disease?
Disease control CompletedThis study tested whether dupilumab, a drug already used for asthma and eczema, can help people with bullous pemphigoid, a painful blistering skin condition. 106 adults received either dupilumab or a placebo, plus standard steroid treatment. The main goal was to see if more peopl…
Matched conditions: BULLOUS PEMPHIGOID
Phase: PHASE2, PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New study tests easier treatment for blistering skin disease
Disease control CompletedThis study tested two ways to treat bullous pemphigoid, a severe blistering skin condition. One group used strong steroid creams for 9 months, while the other used steroids plus methotrexate for 4 weeks, then methotrexate alone for 8 months. The goal was to see if the combination…
Matched conditions: BULLOUS PEMPHIGOID
Phase: PHASE3 • Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
One-Dose hope for blistering skin disease?
Disease control CompletedThis study tested whether a single cycle of rituximab can control bullous pemphigoid, a severe blistering skin condition. Eighteen adults with steroid-dependent or relapsing disease were enrolled. Researchers checked disease control weekly for a month and then monthly for two yea…
Matched conditions: BULLOUS PEMPHIGOID
Phase: PHASE3 • Sponsor: University Hospital, Rouen • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New antibody shows promise for blistering skin disease
Disease control CompletedThis phase 2 trial tested avdoralimab, an antibody that blocks a specific immune signal, added to standard steroid cream for bullous pemphigoid—a severe blistering skin condition mostly affecting older adults. Fifteen participants received the combination to see if it leads to co…
Matched conditions: BULLOUS PEMPHIGOID
Phase: PHASE2 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New shot could tame blistering skin disease and cut steroid use
Disease control CompletedThis study tested a drug called efgartigimod in 98 adults with moderate to severe bullous pemphigoid, a condition causing painful blisters and itching. The goal was to see if the drug could control the disease and allow patients to stop taking steroids. The trial was split into t…
Matched conditions: BULLOUS PEMPHIGOID
Phase: PHASE2, PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Study reveals bone risks from common skin treatment
Knowledge-focused CompletedThis study looked at 47 people with bullous pemphigoid, a blistering skin condition, who were treated with high-dose topical corticosteroids (clobetasol propionate) for 6 months. Researchers measured bone mineral density at the start, at 3 months, and at 6 months to see if the tr…
Matched conditions: BULLOUS PEMPHIGOID
Phase: PHASE4 • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Does a potent steroid cream cause fluid retention? new study investigates
Knowledge-focused CompletedThis study measured fluid retention in 30 people with bullous pemphigoid who were treated with a strong steroid cream (clobetasol propionate). Researchers used bioimpedance to track changes in body water over 30 days. The goal was to understand if the cream causes fluid buildup a…
Matched conditions: BULLOUS PEMPHIGOID
Phase: PHASE4 • Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC